Year Founded
2020
Ownership
Private
Employees
~100
Stage
Preclinical
Modalities
Autologous cell therapyRegulatory T cell therapy

GentiBio General Information

Developing engineered regulatory T cell platform with lead program in Type 1 diabetes entering IND-enabling studies in 2021

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

GNTI-122
Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to GentiBio's pipeline data

Book a demo

Key Partnerships

Bristol Myers Squibb

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

GentiBio Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view GentiBio's complete valuation and funding history, request access »

GentiBio Investors

Bristol Myers Squibb
Investor Type: Venture Capital
Holding: Minority
OrbiMed Advisors
Investor Type: Venture Capital
Holding: Minority
RA Capital Management
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 5 investors. Get the full list »